Table 1.
Patient demographics and baseline disease characteristics (safety analysis set).
| Total (N = 36) | |
|---|---|
| Median age, years (range) | 63 (34–83) |
| Gender, n (%) | |
| Female | 21 (58) |
| Male | 15 (42) |
| Median number of prior chemotherapy regimens (range) | 4 (1–≥6)a |
| Previous treatment | |
| Immunotherapy | 4 (11) |
| Hormonal therapy | 2 (6) |
| Chemotherapy | 32 (89) |
| Systemic therapyb | 7 (19) |
| Other | 11 (31) |
| Radiotherapy | 20 (56) |
| ECOG performance status,c n (%) | |
| 0 | 18 (50) |
| 1 | 18 (50) |
| Primary tumor site, n (%) | |
| Colorectald | 9 (25) |
| Ovary | 7 (19) |
| Lung | 6 (17) |
| Cervix | 4 (11) |
| Mesothelioma | 3 (8) |
| Prostate | 2 (6) |
| Othere | 5 (14) |
aThree patients unknown in total: 1 in cohort 2 and 2 in cohort 7.
bIncludes chemotherapy, anti-VEGF inhibitors, targeted antibodies, and investigational agents.
c0, fully active; 1, restricted in physically strenuous activity.
dIncludes colon, colorectal, colorectal carcinoma, rectal, and sigmoid.
eOther: esophagus, pancreas, parotid gland, small bowel, stomach.